Anticoagulants directs oraux: fiche de transparence et texte utilisé pour la rédaction des AMM ,
fiche de transparence et texte utilisé pour la rédaction des AMM, 2011. ,
Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, issue.26, pp.3632499-510, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00724645
Once daily oral rivaroxaban versus placebo in the long term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study, Blood, 2009. ,
Apixaban in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.364, issue.9, pp.806-817, 2011. ,
DOI : 10.1056/NEJMoa1007432
Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-1151, 2009. ,
DOI : 10.1056/NEJMoa0905561
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation, The American Journal of Cardiology, vol.110, issue.3, pp.110453-460, 2012. ,
DOI : 10.1016/j.amjcard.2012.03.049
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thromb Haemost, issue.5, pp.2012-107985 ,
Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment, Am Heart J, issue.3, pp.159348-353, 2010. ,
Randomized evaluation of long term anticoagulant therapy, warfarin compared with dabigatran, Am Heart J, vol.361, pp.1139-1151, 2009. ,
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvanvular atrial fibrillation The American Journal of cardiology, pp.1001419-1426, 2007. ,
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban, Journal of Pharmacology and Experimental Therapeutics, vol.338, issue.1, pp.372-80, 2011. ,
DOI : 10.1124/jpet.111.180240
Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-992, 2011. ,
DOI : 10.1056/NEJMoa1107039
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin, British Journal of Clinical Pharmacology, vol.86, issue.2 ,
DOI : 10.1111/j.1365-2125.2012.04218.x
Practical guide on the use of new oral anticoagulants in patients with non valvular atrial fibrillation: executive summary, European Heart Journal, vol.15, pp.625-651, 2013. ,
New oral anticoagulants for atrial fibrillation: A review of clinical trials( 30)%+*3, 10#( )*'#(4&$1"(51*$%6-"(+&-1#( +%'6()"1'%81"#(51"#+1%5$%&'#()9*'$%+&*,-.*'$, pp.75-76 ,
938! a.9;:.4,7%8b! A$09774a,%! 8I0-39043,<:%! ,#3749@:.4,7%b! ,#37f@74#,%##%b! ,#37474@A,1,%##%! 9:! ,#3740:8@:.4,(30)%+*3, 7%!9:!-$7,@471,<:%W! ! 210"#()*'#( 4&$1"( "D"1+%+"( 5&-1( +"#( 30)%+*3#( +%'6( )"1'%81"#( 51"#+1%5$%&'#( )9*'$%+&*, pp.7-8 ,
($1*'+I"()9J,"(*55*1$ ,
#3,@94a:.43,9#!974, pp.78-79 ,